Latest News and Press Releases

TEL-AVIV, Israel, Dec. 31, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...

TEL-AVIV, Israel, Dec. 30, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...

The positive results from the pharmacokinetic study support the continuation of the ERADICATE Hp study - a Phase III clinical study currently underway in the U.S., evaluating RHB-105 as a...

The first patients have been dosed in the ERADICATE Hp study - a randomized, double-blind, placebo-controlled, Phase III study evaluating RHB-105 as a first-line therapy for H. pylori bacterial...

First patient has been recruited and dosed in the MAP US study - a randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the safety and efficacy of RHB-104 for...

The Company and its co-development partner, IntelGenx Corp., held a Scientific Advice meeting with the German pharmaceuticals regulation authority (BfArM) and plan to submit a Marketing...

Key highlights include: Commencement of the MAP US study – a Phase III clinical study in North America and Israel with RHB-104 for the treatment of Crohn's disease Commencement of the...

TEL-AVIV, Israel, Oct. 31, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...

RedHill has initiated the patient screening process in the ERADICATE Hp study - a randomized, double-blind, placebo-controlled Phase III study to evaluate the safety and efficacy of RHB-105 as a...

TEL-AVIV, Israel, Oct. 23, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...